Home › a Biogen blames lower-than-expected Tecfidera sales partly on safety concerns
 

Keywords :   


a Biogen blames lower-than-expected Tecfidera sales partly on safety concerns

2015-04-24 22:54:30| Biotech - Topix.net

Biogen's Tecfidera was the biggest locally-developed drug to be approved in the U.S. in 2013. It's expected to make more than $4 billion in revenue in 2018.

Tags: sales safety concerns partly

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Atlantic Tropical Weather Outlook
06.10Tropical Storm Milton Graphics
06.10Tropical Storm Milton Public Advisory Number 3A
06.10Summary for Tropical Storm Milton (AT4/AL142024)
06.10Eastern North Pacific Tropical Weather Outlook
06.10Hurricane Leslie Graphics
06.10Hurricane Kirk Graphics
06.10Hurricane Leslie Forecast Discussion Number 15
More »